TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6370030
Drug: Chlorprothixene 2
Normalized name: chlorprothixene 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorprothixene 2 mg/kg orally
Study: 25096067
Drug: vemurafenib, 960
Approvals — FDA: no, EMA: no, PMDA: no
Description: vemurafenib, 960 mg orally twice daily
Study: 25096067
Drug: dacarbazine, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: dacarbazine, 1,000 mg/m2 intravenously every 3 weeks
Study: 11939810
Drug: 0.1% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tazarotene gel applied twice daily (T + T)
Study: 11939810
Drug: 0.1% tazarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tazarotene gel applied once daily and vehicle gel once daily (T + V)
Study: 11939810
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel applied twice daily (V + V)
Study: 2355823
Drug: Phosphate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate loading (1000 mg of tribasic sodium phosphate, four times daily for 6 days)
Study: 122406
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg haloperidol
Study: 122406
Drug: Prolactin plus
Normalized name: prolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolactin plus luteinizing hormone
Study: 30939483
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (Canagliflozin, Empagliflozin, Dapagliflozin)
Study: 23187044
Drug: Paraffin bath
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin bath therapy (5 times per week, for 3-week duration)
Study: 23187044
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no paraffin bath therapy)
Study: 22025157
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg orally once a day) + Placebo
Study: 22025157
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg orally once a day) + R1507 (9 mg/kg weekly)
Study: 22025157
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg orally once a day) + R1507 (16 mg/kg every 3 weeks)
Study: 22025157
Drug: R1507 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1507 (9 mg/kg weekly)
Study: 12045122
Drug: Prolastin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin (60 mg/kg) administered in four infusions at weekly intervals
Study: 10213433
Drug: 3 microg/mL(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 microg/mL(‐1) of PPF and 0.5 ng/mL(‐1) of SUF in group I (GI)
Study: 10213433
Drug: 3 microg/mL(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 microg/mL(‐1) of PPF and 1 ng/mL(‐1) of SUF in group II (GII)
Study: 655282
Drug: Desipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (50 mg)
Study: 29133320
Drug: Usual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physical therapy (Control group)
Study: 19253234
Drug: High-dose isotretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isotretinoin (>0.5 mg/kg per day)
Study: 19253234
Drug: Low-dose isotretinoin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isotretinoin (<0.5 mg/kg per day)
Study: 15495821
Drug: Puerarin injection
Normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin injection (500 mg per day for 2 weeks)
Study: 11560455
Drug: bupropion, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion, 300 mg/d
Study: 7522124
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy
Study: 9783890
Drug: High dose-volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose-volume group
Study: 3169110
Drug: Cicloprolol 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicloprolol 25 mg
Study: 2904826
Drug: Cicloprolol 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicloprolol 50 mg
Study: 2904826
Drug: Cicloprolol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicloprolol 100 mg
Study: 3169110
Drug: Cicloprolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicloprolol (up to 200 mg)
Study: 3169110
Drug: Prenalterol 50
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol 50 mg
Study: 26265125
Drug: Mannitol treatment
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol treatment (n=1533)
Study: 26265125
Drug: Nonmannitol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmannitol treatment (n=993)
Study: 26265125
Drug: Mannitol treatment
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol treatment in patients with larger baseline hematomas (≥15 mL)
Study: 26265125
Drug: Mannitol treatment
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol treatment
Study: 23765639
Drug: Vardenafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (10 mg/day, for 12 weeks)
Study: 2894399
Drug: DTP-AC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-AC vaccine
Study: 2894399
Drug: DTP-WC vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP-WC vaccine
Study: 29102669
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of filtered air containing particulate mixture (PM 10, PM 2.5, PM 1.0 and PM 0.5 µm)
Study: 29102669
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of filtered air mixture (control)
Study: 27377521
Drug: Single-Dose (SID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Dose (SID) bowel preparation
Study: 27377521
Drug: Split-Dose (SPD1)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-Dose (SPD1) bowel preparation
Study: 27377521
Drug: Split-Dose (SPD2)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-Dose (SPD2) bowel preparation
Study: 24526078
Drug: Non-operative caries
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative caries treatment and prevention (NOCTP) programme
Study: 23363790
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with dendritic cell and cytokine-induced killer cell (DC-CIK) immunotherapy
Study: 17964871
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy + granulocyte-colony stimulating factor (5 microg/kg/day for 6 days)
Study: 17964871
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy + granulocyte-colony stimulating factor (15 microg/kg/day s.c. for 6 days)
Study: 17964871
Drug: granulocyte-colony stimulating
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: granulocyte-colony stimulating factor treatment
Study: 15642561
Drug: atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin + amlodipine
Study: 15642561
Drug: atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin + placebo
Study: 11509086
Drug: Vinpocetine in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine in combination with low‐molecular weight dextran (n = 15)
Study: 9446908
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of all individuals in a class together with family members of positive cases
Study: 9446908
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of only egg positive cases
Study: 7916157
Drug: High-dose neuroleptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose neuroleptic treatment (above 375 mg equivalent of chlorpromazine)
Study: 7916157
Drug: Low-dose neuroleptic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose neuroleptic treatment (375 mg equivalent of chlorpromazine or below)
Study: 3282336
Drug: Acyclovir 200
Normalized name: acyclovir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 200 mg taken orally three times daily for six months
Study: 3282336
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally three times daily for six months
Study: 24853643
Drug: Cholecalciferol 50,000
Normalized name: CHOLECALCIFEROL 50,000UNIT TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 50,000 IU with 0 g fat (Group 1)
Study: 24853643
Drug: Cholecalciferol 50,000
Normalized name: CHOLECALCIFEROL 50,000UNIT TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 50,000 IU with 15 g fat (Group 2)
Study: 24853643
Drug: Cholecalciferol 50,000
Normalized name: CHOLECALCIFEROL 50,000UNIT TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 50,000 IU with 30 g fat (Group 3)
Study: 23489780
Drug: Ultrasound-guided percutaneous
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided percutaneous drainage and alcohol sclerotherapy with single-session multiple injections
Study: 19663091
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus rehabilitation training
Study: 15238420
Drug: Interferon‐alpha (IFN‐alpha)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐alpha (IFN‐alpha) maintenance therapy
Study: 11740135
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 25-50 mg once daily
Study: 22985218
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi exercise (1 hour per session, twice a week for 12 weeks)
Study: 20451040
Drug: Methylprednisolone (32-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (32-8 mg once daily for 20 days)
Study: 28501884
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg on the first day, followed by 100 mg once daily for 20 days)
Study: 19126019
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of 2025 U Botulinum toxin type A (BTA)
Study: 16787142
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using LHRH agonist or orchiectomy plus dexamethasone and somatostatin analogue
Study: 10385667
Drug: 9 million
Normalized name: INTERFERON ALFA-2A,RECOMBINANT 9 MILLION UNT/SYR INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 million units (MU) of IFN‐alpha‐2a, Roferon‐A, thrice weekly for 6 months
Study: 2531606
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine
Study: 6495087
Drug: Intramuscular atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular atropine
Study: 6401946
Drug: Intermittent intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intraoperative antibiotic irrigation
Study: 28315149
Drug: Myofunctional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofunctional therapy (MT)
Study: 31103811
Drug: Flap fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flap fixation using adhesive tissue glue (FF-G)
Study: 29508899
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin (1.8 mg/m2 per cycle for ≤6 cycles)
Study: 29508899
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC: fludarabine/cytarabine [ara‐C]/granulocyte colony‐stimulating factor, or ara‐C plus mitoxantrone, or high‐dose ara‐C for ≤4 cycles)
Study: 17898949
Drug: Tongluo yangyin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongluo yangyin recipe (TLYYR) 200 mL in water decoction daily for 28 days
Study: 17898949
Drug: Vitamin B1
Normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B1 100 mg and Vitamin B12 250 microg administered daily via intramuscular injection for 28 days
Study: 15172082
Drug: Patch E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch E2 (delivering 50 microg per day, two patches per week)
Study: 7863255
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg at night
Study: 2815851
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg digoxin tablets
Study: 2815851
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg digoxin capsules
Study: 2815851
Drug: Cumulative urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative urinary excretion of digoxin
Study: 1097099
Drug: Adriamycin (40-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (40-75 mg/m intravenously every 3 weeks)
Study: 31834217
Drug: Robotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic treatment using a set of 4 devices
Study: 25678773
Drug: Topical recombinant
Normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical recombinant bovine basic fibroblast growth factor (rb‐bFGF) and 0.5% levofloxacin
Study: 22998746
Drug: Patching daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching daily 6 days weekly for 8 hr or more
Study: 22998746
Drug: Patching daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching daily 6 days weekly
Study: 12766664
Drug: Nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiinflammatory drugs (NSAIDs) after tonsillectomy
Study: 1573126
Drug: 5-HT2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT2 receptor antagonist, ritanserin
Study: 4014253
Drug: Pediatric extension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric extension set for drug delivery
Study: 31662003
Drug: Regional arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional arterial infusion (RAI) combined with early enteral nutrition (EEN)
Study: 25069650
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human thrombopoietin (rhTPO), administered subcutaneously at a daily dose of 15,000 U from the first day after transplantation.
Study: 25069650
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rhTPO treatment).
Study: 25069650
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human thrombopoietin (rhTPO) and control group (no rhTPO treatment).
Study: 23212147
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg once daily (M group)
Study: 23212147
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg once daily (S group)
Study: 23212147
Drug: Antimuscarinic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic therapy (Control group)
Study: 12784978
Drug: Quixil fibrin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quixil fibrin glue (0.5 mL to each tonsillar fossa and 0.5 mL to the nasopharynx in adenoidectomy)
Study: 11014398
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) distraction during physical therapy
Study: 11014398
Drug: No distraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No distraction during physical therapy
Study: 8345812
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol diet (800 mg/d)
Study: 8345812
Drug: Low cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low cholesterol diet (250 mg/d)
Study: 2953318
Drug: Hydration plus
Normalized name: Biotrue Hydration Plus Multi-Purpose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration plus intravenously administered clodronate disodium, 4 mg/kg of body weight per day for three days (Rx-2)
Study: 2953318
Drug: Hydration plus
Normalized name: Biotrue Hydration Plus Multi-Purpose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration plus intravenously administered clodronate disodium, 12 mg/kg of body weight given once only (Rx-3)
Study: 29436756
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg every 2 weeks (increased to 150 mg every 2 weeks at week 12 if necessary)
Study: 19463374
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg daily maintenance dose
Study: 19463374
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily maintenance dose
Study: 12924542
Drug: SQV 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV 1400 mg without itraconazole
Study: 12924542
Drug: SQV 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV 1200 mg with itraconazole
Study: 12924542
Drug: SQV 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV 800 mg with itraconazole
Study: 11039131
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sodium cromoglycate (SCG) 20 min before exercise
Study: 11039131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sodium cromoglycate (SCG) 20 min before exercise
Study: 11039131
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sodium cromoglycate (SCG) 120 min before exercise
Study: 11039131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sodium cromoglycate (SCG) 120 min before exercise
Study: 11039131
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg SCG 20 min before exercise
Study: 11039131
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg SCG 120 min before exercise
Study: 11039131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg SCG 20 min before exercise
Study: 11039131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg SCG 120 min before exercise
Study: 8479193
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) in combination with external beam (n = 27)
Study: 29751787
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a SC 44 μg 3×/week
Study: 29751787
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a SC 22 μg 3×/week
Study: 29751787
Drug: Placebo/delayed treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/delayed treatment (DTx)
Study: 18702958
Drug: Miglitol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (50 mg)
Study: 12069449
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance ≤ 40 ml x min(‐1)
Study: 12069449
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance from 41 to 55 ml x min(‐1)
Study: 12069449
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance from 71 to 85 ml x min(‐1)
Study: 29873212
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention combined with diazepam (2.5 mg once, twice a day)
Study: 29873212
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment of sudden hearing loss (Control group)
Study: 23113597
Drug: Resonance frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resonance frequency analysis (RFA) measurements at 8 weeks post-implant placement
Study: 23113597
Drug: Resonance frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resonance frequency analysis (RFA) measurements at implant placement
Study: 22240263
Drug: Colestimide 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestimide 3 g/day
Study: 17554695
Drug: Sulfadoxine‐pyrimethamine (IPTi)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (IPTi) after first dose
Study: 17554695
Drug: Sulfadoxine‐pyrimethamine (IPTi)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (IPTi) after second dose
Study: 17554695
Drug: Sulfadoxine‐pyrimethamine (IPTi)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (IPTi) after third dose
Study: 17554695
Drug: Sulfadoxine‐pyrimethamine (IPTi)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (IPTi) after last dose
Study: 15803071
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and spinal stabilization exercises (30 minutes, 8 treatments over 8 weeks)